Our Pharma Insights Blog
The FDA approved 7 new drugs in August 2026. These approvals introduced new treatment approaches…
Comparator sourcing is one of the most consequential decisions in trial design. Get it wrong,…
Salim Shaikh, Founder and CEO of Spring Bio Solution, has authored a new article, “The…
6 new drugs were approved by the FDA in the month of July. These drugs…
A drug can look brilliant in a single-arm study and fail completely once placed head-to-head…
High-value oncology drugs often come with equally complex clinical supply requirements. OGSIVEO® (nirogacestat) is one…
Every few months, someone in a regulatory affairs forum asks a version of the same…
The Ancillary Problem in Speciality Sourcing: A Market-Intelligence Look at Fintepla® (fenfluramine)
In specialty and comparator sourcing, the working assumption is that the molecule is the hard…
The clock on exclusivity doesn’t start when a patent expires; it starts the moment a…
The NCE-1 date for 𝗢𝗥𝗦𝗘𝗥𝗗𝗨® (𝗘𝗹𝗮𝗰𝗲𝘀𝘁𝗿𝗮𝗻𝘁) is January 27, 2027. While patent protection may extend…
When a new therapy enters the market, it frequently shifts the baseline standard of care,…
The FDA approvals in April 2026 introduced two important drugs that could create major opportunities.…